|
Objective: To study the Yanbian area population with type 2 diabetes (Type 2 Diabetes Mellitus, T2DM) patients with CD36 intron 3 (intron3) [TG] repeat polymorphism distribution of the gene polymorphism on diabetic nephropathy (Diabetes Nephropathy DN) of the occurrence, development impact, and to study the risk factors of DN. Research object and method: object: randomly selected healthy in our hospital 80: 38 men, 42 women, age 45.6 17.9 years of age as a normal control group, the clinical and laboratory tests were normal, rule out the liver, kidney, endocrine and cardiovascular and cerebrovascular diseases. T2DM patients hospitalized in the hospital Endocrinology selected in December 2004 - December 2009 193 patients (male 106, female 87 cases), age 54.0 ± 12.1 years as T2DM group. T2DM diagnosis is based on the 1999 WHO diagnostic criteria exclude pregnancy, tumors, trauma, acute infection, heart and liver disease, and use of angiotensin-converting enzyme inhibitors, hydroxymethyl glutaryl coenzyme A reductase inhibitors thiazole TZDs. Non-DN group (UAER lt; 0.5g/24h) and DN group (UAER gt; 0.5g/24h). The all subjects objects are Yanbian area without T2DM patients were divided according to the 24-hour urinary albumin excretion rate (UAER) unrelated individuals. Methods: The polymerase chain reaction (PCR) and PCR direct sequencing method Yanbian area population 193 T2DM patients and 80 normal control group, CD36 intron 3 [TG] repeat polymorphism distribution while 193 T2DM patients (91 cases of concurrent DN) clinical data and biochemical parameters were analyzed retrospectively. Analysis using the SPSS 17.0 software package. CD36 intron 3 [TG repeat polymorphism distribution was used to compare the X2 test. 193 patients with T2DM biochemical indicators data are presented as mean ± standard deviation (X ± s) said, t test; rate line X2 test, correlation logistic regression analysis, p lt; 0.05 for the difference was statistically significant. Results: (1) CD36 intron 3 [TG] repeat polymorphism in the distribution of the normal control group and T2DM group no significant difference (p gt; 0.05). (2) In patients with T2DM, HLD-C anomaly (HLD-C <0.9 mmol / L) group HLD-C normal abnormal; LDL-C (LDL-C> 3.12 mmol / L) group with normal LDL-C CD36 intron between groups [TG] repeat polymorphism distribution significantly different (p lt; 0.05). (3) in T2DM patients, high CRP (CRP gt; 5.Omg / L) group and normal CRP group CD36 intron 3 [TG] repeat polymorphism distribution there is a significant difference p lt; 0.05). (4) in patients with T2DM, high body mass index (BMI ≥ 24.0kg/m2) group and the normal BMI group CD36 intron 3 [TG repeat polymorphism distribution significantly different (p lt; 0.05). (5) biochemical data T2DM patients with DN group and non-DN group comparison shows course of the disease, high blood pressure, low-density lipoprotein, serum creatinine significant difference (p lt; 0.05 or p lt; 0.01), age, blood glucose, glycosylated hemoglobin, cholesterol, triglycerides, high-density lipoprotein, and body mass index was no difference (all p gt; 0.05). (6) Logistic regression analysis showed that: DN occurrence and course of the disease, high blood pressure and C-reactive protein levels are closely related (p lt; 0.01), age, blood glucose, glycosylated hemoglobin, serum creatinine, cholesterol, triglycerides, high-density lipoprotein protein, low-density lipoprotein levels, and is independent of the body mass index (all p gt; 0.05). Conclusion: (1) CD36 intron 3 [TG] repeat polymorphism with type 2 diabetes in patients with low HLD-C, LDL-C, high CRP levels and high body mass index. (2) the course of the disease, high blood pressure, CRP and LDL levels in patients with type 2 diabetes is the development of important risk factors of DN.
|